David M. Burger
About
David M. Burger is a scholar working on Infectious Diseases, Virology and Epidemiology.
According to data from OpenAlex, David M. Burger has authored 497 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 358 papers in Infectious Diseases, 190 papers in Virology and 123 papers in Epidemiology. Recurrent topics in David M. Burger's work include HIV/AIDS drug development and treatment (311 papers), HIV Research and Treatment (190 papers) and HIV/AIDS Research and Interventions (133 papers). David M. Burger is often cited by papers focused on HIV/AIDS drug development and treatment (311 papers), HIV Research and Treatment (190 papers) and HIV/AIDS Research and Interventions (133 papers). David M. Burger collaborates with scholars based in Netherlands, United Kingdom and United States. David M. Burger's co-authors include Peter P. Koopmans, Rob E. Aarnoutse, Roger J. M. Brüggemann, Kees Brinkman, Hadewych J. M. ter Hofstede, C.P.W.G.M. Verwey-van Wissen, Patricia W. H. Hugen, Jan Smeıtınk, Yechiel A. Hekster and Paul E. Verweij and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Gastroenterology.
In The Last Decade
David M. Burger
486 papers receiving 13.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David M. Burger Netherlands | 56 | 9.0k | 4.4k | 3.3k | 2.1k | 2.0k | 497 | 13.4k | ||
| Saye Khoo United Kingdom | 50 | 6.0k 0.7× | 3.0k 0.7× | 2.1k 0.6× | 1.5k 0.7× | 1.5k 0.8× | 331 | 9.0k | ||
| David Back United Kingdom | 60 | 8.0k 0.9× | 4.7k 1.1× | 2.1k 0.6× | 2.6k 1.3× | 1.8k 0.9× | 364 | 13.4k | ||
| Angela D. M. Kashuba United States | 56 | 6.7k 0.7× | 4.9k 1.1× | 2.9k 0.9× | 1.1k 0.5× | 839 0.4× | 314 | 11.2k | ||
| Courtney V. Fletcher United States | 48 | 5.5k 0.6× | 4.2k 0.9× | 2.1k 0.6× | 891 0.4× | 1.3k 0.7× | 230 | 8.4k | ||
| Gary Maartens South Africa | 62 | 10.4k 1.2× | 2.9k 0.7× | 6.5k 2.0× | 947 0.5× | 1.5k 0.8× | 376 | 14.0k | ||
| Laurent A. Décosterd Switzerland | 50 | 3.8k 0.4× | 2.2k 0.5× | 1.5k 0.5× | 1.2k 0.6× | 673 0.3× | 270 | 10.1k | ||
| Giovanni Di Perri Italy | 43 | 3.8k 0.4× | 1.6k 0.4× | 2.2k 0.7× | 727 0.4× | 825 0.4× | 418 | 7.7k | ||
| Tomáš Cihlář United States | 51 | 7.8k 0.9× | 2.6k 0.6× | 2.8k 0.8× | 672 0.3× | 708 0.4× | 143 | 11.3k | ||
| Edward P. Acosta United States | 49 | 5.7k 0.6× | 4.0k 0.9× | 1.6k 0.5× | 884 0.4× | 1.1k 0.5× | 214 | 8.1k | ||
| Thierry Buclin Switzerland | 59 | 4.0k 0.4× | 1.7k 0.4× | 2.0k 0.6× | 2.0k 1.0× | 659 0.3× | 336 | 12.6k |
Countries citing papers authored by David M. Burger
Since
Specialization
Citations
This map shows the geographic impact of David M. Burger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Burger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Burger more than expected).
Fields of papers citing papers by David M. Burger
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David M. Burger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Burger. The network helps show where David M. Burger may publish in the future.
Co-authorship network of co-authors of David M. Burger
This figure shows the co-authorship network connecting the top 25 collaborators of David M. Burger. A scholar is included among the top collaborators of David M. Burger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Burger. David M. Burger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jacobs, Tom, et al.. (2024). Availability and stock‐outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda. HIV Medicine. 25(7). 805–816.
2.
Burger, David M., Nicole M. A. Blijlevens, Luuk B. Hilbrands, et al.. (2024). Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians. Clinical Pharmacokinetics. 63(11). 1529–1546.
3.
Waalewijn, Hylke, Alexander J. Szubert, Roeland E. Wasmann, et al.. (2023). First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Clinical Infectious Diseases. 77(6). 875–882.
4.
McIlleron, Helen, David M. Burger, Diana M. Gibb, et al.. (2021). Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology. 88(2). 403–415.
5.
Muilwijk, Eline W., Dylan W. de Lange, Jeroen Schouten, et al.. (2020). Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. Antimicrobial Agents and Chemotherapy. 64(10).
6.
Huiskes, Victor J B, et al.. (2019). Effectiveness of medication review on the number of drug‐related problems in patients visiting the outpatient cardiology clinic: A randomized controlled trial. British Journal of Clinical Pharmacology. 86(1). 50–61.
7.
Burger, David M., et al.. (2018). Combining Fill-Level Sensing With Route Optimization for a More Efficient Waste Collection. Zenodo (CERN European Organization for Nuclear Research).
8.
Bouma, Margriet, David M. Burger, Joost P.H. Drenth, et al.. (2018). Safe use of proton pump inhibitors in patients with cirrhosis. British Journal of Clinical Pharmacology. 84(8). 1806–1820.
9.
Flint, Robert B., Rob ter Heine, Edwin Spaans, et al.. (2018). Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. European Journal of Clinical Pharmacology. 74(12). 1585–1591.
10.
Smolders, Elise J., Karel J. van Erpecum, Raoel Maan, et al.. (2017). Ribavirin steady‐state plasma level is a predictor of sustained virological response in hepatitis C–infected patients treated with direct‐acting antivirals. Alimentary Pharmacology & Therapeutics. 46(9). 864–872.
11.
Gevers, Tom J.G., et al.. (2016). Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.. Data Archiving and Networked Services (DANS). 74(5). 225–7.
12.
Boucher, Charles A., Eline Op de Coul, Michiel A. van Agtmael, et al.. (2013). [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].. PubMed. 157(27). A6063–A6063.
13.
Aitken, Susan C., Elton R. Kisanga, Chipepo Kankasa, et al.. (2013). Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. Journal of Antimicrobial Chemotherapy. 68(11). 2609–2615.
14.
Boucher, Charles A., J.T. Brouwer, David M. Burger, et al.. (2013). Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.. PubMed. 71(7). 377–85.
15.
Kampen, Jeroen J. A. van, Peter C. Burgers, Lennard J. M. Dekker, et al.. (2010). Correction: Ultra-Fast Analysis of Plasma and Intracellular Levels of HIV Protease Inhibitors in Children: A Clinical Application of MALDI Mass Spectrometry. PLoS ONE. 5(7).
16.
Brüggemann, Roger J. M., Jan‐Willem C. Alffenaar, Nicole M. A. Blijlevens, et al.. (2009). Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. Clinical Infectious Diseases. 48(10). 1441–1458.
17.
Burger, David M., et al.. (2006). Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 50(10). 3336–3342.
18.
Bergshoeff, Alina S, David M. Burger, Laura Farrelly, et al.. (2005). Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).. PubMed. 10(2). 239–46.
19.
Dieleman, Jeanne P., Annemarie M. C. van Rossum, Miriam Sturkenboom, et al.. (2003). Persistent Leukocyturia and Loss of Renal Function in a Prospectively Monitored Cohort of HIV-Infected Patients Treated with Indinavir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 32(2). 135–142.
20.
Hugen, Patricia W. H., C.P.W.G.M. Verwey-van Wissen, David M. Burger, et al.. (1999). Simultaious determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.. Journal of Chromatography B. 727. 139–149.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Saye Khoo Breakdown of academic impact, for papers by David Back Breakdown of academic impact, for papers by Angela D. M. Kashuba Breakdown of academic impact, for papers by Courtney V. Fletcher Breakdown of academic impact, for papers by Gary Maartens Breakdown of academic impact, for papers by Laurent A. Décosterd Breakdown of academic impact, for papers by Giovanni Di Perri Breakdown of academic impact, for papers by Tomáš Cihlář Breakdown of academic impact, for papers by Edward P. Acosta Breakdown of academic impact, for papers by Thierry Buclin